Stock Events

Stock Events

Ardelyx 

$3.93
247
-$0.13-3.33% 15:32 Today

Statistics

Day High
4.09
Day Low
3.91
52W High
8.4
52W Low
3.86
Volume
997,249
Avg. Volume
4,076,953
Mkt Cap
1.01B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

29OctExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.17
-0.11
-0.04
0.02
Expected EPS
-0.01458
Actual EPS
N/A

Financials

-15.12%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
407.32MRevenue
-61.6MNet Income

Analyst Ratings

13.71Average Price Target
The highest estimate is 18.00.
From 7 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ARDX. It's not an investment recommendation.
Amazon
39
AMZN
Apple
32
AAPL
Tesla
29
TSLA
NVIDIA
29
NVDA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Astrazeneca
AZN
Mkt Cap242.64B
AstraZeneca competes in the renal disease space with their drug Lokelma, a direct competitor to Ardelyx's tenapanor for hyperphosphatemia in patients with chronic kidney disease.
Sanofi
SNY
Mkt Cap104.76B
Sanofi, with its broad portfolio in diabetes and renal diseases, competes indirectly through its treatments that manage complications related to CKD, potentially overlapping with Ardelyx's market.
AMGEN
AMGN
Mkt Cap224.63B
Amgen's Parsabiv, used for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease on hemodialysis, competes in the CKD space, indirectly challenging Ardelyx.
Abbvie
ABBV
Mkt Cap440.83B
AbbVie, through its acquisition of Allergan, has products in the gastrointestinal space, which could compete with Ardelyx's focus on irritable bowel syndrome and related conditions.
Bristol-Myers Squibb
BMY
Mkt Cap130.39B
Bristol Myers Squibb, with its acquisition of Reata Pharmaceuticals, enters the CKD and rare disease market, positioning it as a competitor to Ardelyx in the nephrology space.
Akebia Therapeutics
AKBA
Mkt Cap241.86M
Akebia Therapeutics, after merging with Keryx, continues to compete in the hyperphosphatemia and anemia in CKD space, directly against Ardelyx's products.

About

Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Show more...
CEO
Michael G. Raab
Employees
489
Country
United States
ISIN
US0396971071
WKN
000A116X0

Listings

XNAS
US
ARDX
STU
DE
41X.STU
MU
DE
41X.MU
F
DE
41X.F

0 Comments

Share your thoughts

FAQ

What is Ardelyx stock price today?▼
The current price of ARDX is $3.93 USD — it has decreased by -3.33% in the past 24 hours. Watch Ardelyx stock price performance more closely on the chart.
What is Ardelyx stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Ardelyx stocks are traded under the ticker ARDX.
Is Ardelyx stock price growing?▼
ARDX stock has fallen by -0.25% compared to the previous week, the month change is a -24.42% fall, over the last year Ardelyx has showed a -32.36% decrease.
What is Ardelyx market cap?▼
Today Ardelyx has the market capitalization of 1.01B
When is the next Ardelyx earnings date?▼
Ardelyx is going to release the next earnings report on October 29, 2026.
What were Ardelyx earnings last quarter?▼
ARDX earnings for the last quarter are -0.07 USD per share, whereas the estimation was -0.07 USD resulting in a -6.95% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Ardelyx revenue for the last year?▼
Ardelyx revenue for the last year amounts to 407.32M USD.
What is Ardelyx net income for the last year?▼
ARDX net income for the last year is -61.6M USD.
How many employees does Ardelyx have?▼
As of August 18, 2026, the company has 489 employees.
In which sector is Ardelyx located?▼
Ardelyx operates in the Health & Wellness sector.
When did Ardelyx complete a stock split?▼
Ardelyx has not had any recent stock splits.
Where is Ardelyx headquartered?▼
Ardelyx is headquartered in FREMONT, United States.